Scientists of the German Cancer Research Center (Deutsches Krebsforschungszentrum, DKFZ) have found out why specific genes are read as a response to hunger signals such as glucagon or glucocorticoids and, thus, mediate glucose release from the liver. A team of researchers headed by Dr. Anja Krones-Herzig identified the CARM1 molecule as a transcription factor that activates key enzymes of glucose synthesis under certain conditions, thus causing the blood sugar level to rise. A typical feature of metabolic disorders such as type 2 (adult onset) diabetes is that important organs such as liver, muscles, and fatty tissue cease to respond to the pancreatic hormone insulin (insulin resistance), while other, opposing hormones such as glucagon or glucocorticoids continue to unfold their effects. The result is that sugar from the blood is no longer transported to and stored in muscle tissue or the liver. Jointly with team colleagues and researchers from the Institute of Genetics and Center for Molecular Medicine at Cologne University, Krones-Herzig found out that the CARM1 transcription factor plays an important role in the activation of key enzymes of gluconeogenesis.

Depending on the messenger substance cAMP, CARM1 attaches itself to the starting sequence of the blueprints for PEPCK and G6Pase, thus giving the signal for the genes to be read. Another case of disrupted insulin-dependent metabolism is cachexia, a frequent and severe condition associated with advanced cancer. The consequences are weight loss, weakness and increasing failure of organ functions. Group leader Dr. Stephan Herzig plans to investigate with his team whether the same or related genes or gene products - transcription factors, to be more precise - that influence the insulin-dependent metabolism in diabetes, might also play a role in tumor-asociated cachexia. While in diabetes the liver is in the center of attention, in the wasting syndrome (cachexia) researchers are focusing on the metabolism of the muscle tissue. The medium-term goal of the cancer researchers is to find out whether dysregulated components of the insulin signaling cascade might be used as targets for drugs.

If you are evaluating what organic allulose is and how it works, the next question is inevitable: what does it actually do inside the body? Sweetness without consequence sounds appealing, Glyco Mode but formulators, healthcare professionals, and informed consumers want evidence - not marketing language. This article walks through the current scientific understanding of allulose and its effects on blood sugar, insulin, calorie intake, kidney function, liver metabolism, gut tolerance, and long-term safety. Every claim here traces back to published research or regulatory determinations. Allulose has a glycemic index of approximately zero. It does not raise blood glucose and does not trigger a meaningful insulin response. This is not a marginal effect - it is a consistent finding across clinical trials. A double-blind crossover study published in the Journal of Nutritional Science and Vitaminology demonstrated that 5 g of allulose consumed with a meal significantly reduced postprandial blood glucose elevation compared to the same meal without allulose.

The mechanism appears to involve GLP-1 (glucagon-like peptide-1) stimulation: allulose encourages the release of this incretin hormone, which in turn slows gastric emptying and enhances insulin sensitivity. For food formulators, this means organic allulose sweetener can serve a functional role beyond sweetness - it actively helps blunt the glycemic impact of other carbohydrates in a formulation. For diabetic-friendly product claims, this is a meaningful differentiator. It is worth emphasizing that allulose does not lower blood sugar below normal levels. It moderates the spike. The effect is stabilizing, not hypoglycemic. Sugar delivers roughly 4 kcal per gram. Allulose delivers approximately 0.4 kcal per gram - about 90% fewer calories. The reason is straightforward: the human body largely cannot metabolize it. Unlike glucose, which is readily absorbed and oxidized for energy, allulose passes through metabolic pathways inefficiently. Most of what is absorbed is filtered by the kidneys and excreted in urine within 24 to 48 hours.

The small fraction that does undergo metabolism produces minimal caloric yield. This caloric profile has regulatory backing. The FDA permits allulose to be excluded from "Total Sugars" and "Added Sugars" declarations on Nutrition Facts labels (more on labeling nuances below). For product developers targeting calorie reduction without sacrificing mouthfeel or browning, this is one of the few options that works. A common concern - especially among consumers with kidney conditions - is whether a substance primarily excreted through urine places stress on renal function. Multiple toxicology studies, including a 90-day subchronic study and a two-year chronic toxicity study in rats, found no nephrotoxicity at doses far exceeding typical human consumption. Human clinical trials monitoring renal biomarkers (creatinine, BUN, eGFR) have similarly reported no adverse changes. The key distinction is between excretion through the kidneys and damage to the kidneys. Allulose is a small, water-soluble molecule that the kidneys filter efficiently - much like certain vitamins and electrolytes. Efficient filtration is not the same as toxic burden.